Nebenwirkungen · Gobivaz
GOBIVAZ 50 mg solution for injection in pre-filled pen. · Abschnitt 4.8 · PDF-Seite 44–45
HOS-153523 · Präparat HOS-101000
44 In the controlled periods of pivotal trials and through approximately 4 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar between the golimumab and the control groups. Through approximately 4 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T10:38:00Z · SHA-256 b368a4f3ae6dce5887430617ccfcdc36900996af800ff08514415b29e19f2102 · Passage 467816a319ba788ddc50af4dc0227a5c631a0817696433ff3f03a0767b2dd36f · Zeichen 10862–11258 im Abschnitt